In addition, while the EMTc signature score (Fig. 3C) was similar in tumors of prostate cancer patients with wild-type or mutated PTEN, it was higher in tumors of patients with mutated TP53 than of those with wild-type TP53 in the TCGA PRAD cohort (Fig. 3E, F). This evidence concerns the gene TP53 and Familial prostate cancer.